Cargando…

Ceruloplasmin activity and iron chelation treatment of patients with Parkinson’s disease

BACKGROUND: Growing body of evidence suggests that Parkinson’s disease (PD) is associated with oxidative damage via iron accumulation in the substantia nigra (SN). Low ceruloplasmin (CP)-ferroxidase activity has been identified in the SN and the cerebrospinal fluid (CSF) of patients with PD. The iro...

Descripción completa

Detalles Bibliográficos
Autores principales: Grolez, Guillaume, Moreau, Caroline, Sablonnière, Bernard, Garçon, Guillaume, Devedjian, Jean-Christophe, Meguig, Sayah, Gelé, Patrick, Delmaire, Christine, Bordet, Regis, Defebvre, Luc, Cabantchik, Ioav Z, Devos, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4429376/
https://www.ncbi.nlm.nih.gov/pubmed/25943368
http://dx.doi.org/10.1186/s12883-015-0331-3
_version_ 1782371024817356800
author Grolez, Guillaume
Moreau, Caroline
Sablonnière, Bernard
Garçon, Guillaume
Devedjian, Jean-Christophe
Meguig, Sayah
Gelé, Patrick
Delmaire, Christine
Bordet, Regis
Defebvre, Luc
Cabantchik, Ioav Z
Devos, David
author_facet Grolez, Guillaume
Moreau, Caroline
Sablonnière, Bernard
Garçon, Guillaume
Devedjian, Jean-Christophe
Meguig, Sayah
Gelé, Patrick
Delmaire, Christine
Bordet, Regis
Defebvre, Luc
Cabantchik, Ioav Z
Devos, David
author_sort Grolez, Guillaume
collection PubMed
description BACKGROUND: Growing body of evidence suggests that Parkinson’s disease (PD) is associated with oxidative damage via iron accumulation in the substantia nigra (SN). Low ceruloplasmin (CP)-ferroxidase activity has been identified in the SN and the cerebrospinal fluid (CSF) of patients with PD. The iron chelator, deferiprone, reduces the abnormally high levels of iron in the SN. In order to determine CP’s involvement in iron accumulation in SN and PD progression, we aim to compare the ability of iron chelation treatment to reducing both SN iron levels and motor handicap in PD patients according to the level of ceruloplasmin activity. METHODS: We used a moderate chelation protocol with deferiprone (DFP) based on a, 6-month delayed-start paradigm, randomized placebo controlled clinical trial in 40 PD patients. CP-ferroxidase activity was determined in blood and CSF together with the D544E gene polymorphism (rs701753). Iron levels were determined by R2* MRI sequence and the motor handicap by the UPDRS motor score. RESULTS: After 6 to 12 months of DFP treatment, greater reductions in SN iron levels and UPDRS motor scores were obtained in patients with higher serum and CSF levels of CP-ferroxidase activity. After 6 months of DFP treatment, the AT genotype group displayed greater reduction of iron level in the SN with greater CSF and serum levels of CP activity than the AA genotype group. CONCLUSION: Although most of the DFP-treated patients displayed clinical and radiological improvements, those with the lower CP activity appeared to respond better to iron chelation. Larger RCTs are now needed to establish whether pharmacological modulation of CP activity could be an innovative neuroprotective strategy in PD. TRIAL REGISTRATION: FAIR-PARK study (ClinicalTrials.gov reference: NCT00943748; French national reference number: 2008−006842−25). This study was approved by the French Drug Agency (ANSM) and the local institutional review board (“Comité de Protection des Personnes of Lille”). ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12883-015-0331-3) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4429376
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-44293762015-05-14 Ceruloplasmin activity and iron chelation treatment of patients with Parkinson’s disease Grolez, Guillaume Moreau, Caroline Sablonnière, Bernard Garçon, Guillaume Devedjian, Jean-Christophe Meguig, Sayah Gelé, Patrick Delmaire, Christine Bordet, Regis Defebvre, Luc Cabantchik, Ioav Z Devos, David BMC Neurol Research Article BACKGROUND: Growing body of evidence suggests that Parkinson’s disease (PD) is associated with oxidative damage via iron accumulation in the substantia nigra (SN). Low ceruloplasmin (CP)-ferroxidase activity has been identified in the SN and the cerebrospinal fluid (CSF) of patients with PD. The iron chelator, deferiprone, reduces the abnormally high levels of iron in the SN. In order to determine CP’s involvement in iron accumulation in SN and PD progression, we aim to compare the ability of iron chelation treatment to reducing both SN iron levels and motor handicap in PD patients according to the level of ceruloplasmin activity. METHODS: We used a moderate chelation protocol with deferiprone (DFP) based on a, 6-month delayed-start paradigm, randomized placebo controlled clinical trial in 40 PD patients. CP-ferroxidase activity was determined in blood and CSF together with the D544E gene polymorphism (rs701753). Iron levels were determined by R2* MRI sequence and the motor handicap by the UPDRS motor score. RESULTS: After 6 to 12 months of DFP treatment, greater reductions in SN iron levels and UPDRS motor scores were obtained in patients with higher serum and CSF levels of CP-ferroxidase activity. After 6 months of DFP treatment, the AT genotype group displayed greater reduction of iron level in the SN with greater CSF and serum levels of CP activity than the AA genotype group. CONCLUSION: Although most of the DFP-treated patients displayed clinical and radiological improvements, those with the lower CP activity appeared to respond better to iron chelation. Larger RCTs are now needed to establish whether pharmacological modulation of CP activity could be an innovative neuroprotective strategy in PD. TRIAL REGISTRATION: FAIR-PARK study (ClinicalTrials.gov reference: NCT00943748; French national reference number: 2008−006842−25). This study was approved by the French Drug Agency (ANSM) and the local institutional review board (“Comité de Protection des Personnes of Lille”). ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12883-015-0331-3) contains supplementary material, which is available to authorized users. BioMed Central 2015-05-06 /pmc/articles/PMC4429376/ /pubmed/25943368 http://dx.doi.org/10.1186/s12883-015-0331-3 Text en © Grolez et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Grolez, Guillaume
Moreau, Caroline
Sablonnière, Bernard
Garçon, Guillaume
Devedjian, Jean-Christophe
Meguig, Sayah
Gelé, Patrick
Delmaire, Christine
Bordet, Regis
Defebvre, Luc
Cabantchik, Ioav Z
Devos, David
Ceruloplasmin activity and iron chelation treatment of patients with Parkinson’s disease
title Ceruloplasmin activity and iron chelation treatment of patients with Parkinson’s disease
title_full Ceruloplasmin activity and iron chelation treatment of patients with Parkinson’s disease
title_fullStr Ceruloplasmin activity and iron chelation treatment of patients with Parkinson’s disease
title_full_unstemmed Ceruloplasmin activity and iron chelation treatment of patients with Parkinson’s disease
title_short Ceruloplasmin activity and iron chelation treatment of patients with Parkinson’s disease
title_sort ceruloplasmin activity and iron chelation treatment of patients with parkinson’s disease
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4429376/
https://www.ncbi.nlm.nih.gov/pubmed/25943368
http://dx.doi.org/10.1186/s12883-015-0331-3
work_keys_str_mv AT grolezguillaume ceruloplasminactivityandironchelationtreatmentofpatientswithparkinsonsdisease
AT moreaucaroline ceruloplasminactivityandironchelationtreatmentofpatientswithparkinsonsdisease
AT sablonnierebernard ceruloplasminactivityandironchelationtreatmentofpatientswithparkinsonsdisease
AT garconguillaume ceruloplasminactivityandironchelationtreatmentofpatientswithparkinsonsdisease
AT devedjianjeanchristophe ceruloplasminactivityandironchelationtreatmentofpatientswithparkinsonsdisease
AT meguigsayah ceruloplasminactivityandironchelationtreatmentofpatientswithparkinsonsdisease
AT gelepatrick ceruloplasminactivityandironchelationtreatmentofpatientswithparkinsonsdisease
AT delmairechristine ceruloplasminactivityandironchelationtreatmentofpatientswithparkinsonsdisease
AT bordetregis ceruloplasminactivityandironchelationtreatmentofpatientswithparkinsonsdisease
AT defebvreluc ceruloplasminactivityandironchelationtreatmentofpatientswithparkinsonsdisease
AT cabantchikioavz ceruloplasminactivityandironchelationtreatmentofpatientswithparkinsonsdisease
AT devosdavid ceruloplasminactivityandironchelationtreatmentofpatientswithparkinsonsdisease